Massachusetts Financial Services
AIMT

Massachusetts Financial Services’s Aimmune Therapeutics AIMT Stock Holding History

Massachusetts Financial Services’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-379,152
Closed -$6.34M – 920
2020
Q2 		$6.34M Buy
379,152
+30,633
+9% +$520K ﹤0.01% 632
2020
Q1 		$5.03M Buy
348,519
+38,659
+12% +$988K ﹤0.01% 633
2019
Q4 		$10.4M Sell
309,860
-231,357
-43% -$6.47M ﹤0.01% 598
2019
Q3 		$11.3M Buy
541,217
+119,008
+28% +$2.43M ﹤0.01% 597
2019
Q2 		$8.79M Buy
422,209
+2,507
+0.6% +$51.6K ﹤0.01% 636
2019
Q1 		$9.38M Sell
419,702
-272
-0.1% -$6.4K ﹤0.01% 619
2018
Q4 		$10M Buy
419,974
+95,993
+30% +$2.48M ﹤0.01% 595
2018
Q3 		$8.84M Buy
323,981
+63,546
+24% +$1.8M ﹤0.01% 643
2018
Q2 		$7M Buy
260,435
+37,053
+17% +$1.13M ﹤0.01% 659
2018
Q1 		$7.11M Buy
+223,382
New +$7.86M ﹤0.01% 649

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services's AIMT Position: Q3 2020 in Review

Massachusetts Financial Services sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 379,152 shares — an estimated $6.34M sold.

Massachusetts Financial Services first reported a position in AIMT in Q1 2018 and held it in 10 quarters. The position peaked at $11.3M in Q3 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Massachusetts Financial Services reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Massachusetts Financial Services sold 379,152 Aimmune Therapeutics shares in Q3 2020, an estimated $6.34M.
  • Massachusetts Financial Services first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 10 quarters.
  • Massachusetts Financial Services's Aimmune Therapeutics position peaked at $11.3M in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Massachusetts Financial Services's 13F filing for Q3 2020, filed 12 Nov 2020.